Compare MP Materials (MP) vs Roivant Sciences Ltd. Common Shares (ROIV) Price & Performance

MP MaterialsTrade

Roivant Sciences Ltd. Common SharesTrade

Price performance (Past 24H)

Key statistics

MP Materials vs Roivant Sciences Ltd. Common Shares — how do they compare? MP Materials trades at $46.66 (market cap $8.25B), while Roivant Sciences Ltd. Common Shares trades at $34.21 (market cap $25.09B). The key difference: Roivant Sciences Ltd. Common Shares is far larger — about 3× MP Materials's market cap, and Roivant Sciences Ltd. Common Shares is trading nearer its 52-week high, MP Materials nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold MP Materials for 11 Days and Roivant Sciences Ltd. Common Shares for 0 Days on average.

	MP	ROIV
Market Cap	$8.25B	$25.09B
Volume	5,934,023	5,738,571
Sector	Basic Materials	Health
52-Week High	$98.65	$41.81
52-Week Low	$38.10	$16.04
Typical Hold Time	11 Days	0 Days
Enterprise Value	$7.73B	$21.36B

View details →View details →

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

81% Buy19% Sell

Avg holding period · 11 Days

ROIV

100% Buy0% Sell

Avg holding period · 0 Days

Top news

Latest headlines on both assets

Critical metals stocks fall again; builders like USA Rare Earth drop sharply, producers like MP Materials hold better.24/7 Wall Street · 16 hours agoBearish Rare earth stocks drop 3-5% amid sector-wide selloff without company-specific news.24/7 Wall Street · 1 day agoBearish Pentagon invests $400M in MP Materials to break China's rare earth magnet monopoly, GM first to receive non-China magnets.24/7 Wall Street · 4 days agoBullish View details →

ROIV

View details →

About MP Materials

MP Materials mines, refines, and manufactures rare earth materials and magnets in the United States. Its products are used in transportation, energy, robotics, defense, and aerospace applications.

About Roivant Sciences Ltd. Common Shares

Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.